EQRX
42 articles about EQRX
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look. -
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
10/6/2021
EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Absci Corporation, the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, announced a discovery collaboration.
-
Wanting to find out what is fueling the trend, BioSpace solicited the perspectives of a couple of executives who chose the SPAC route.
-
EQRx Appoints Kathy Giusti to Board of Directors
9/27/2021
EQRx today announced the appointment of Kathy Giusti to the Company’s board of directors.
-
EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021
9/17/2021
EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, announced a late-breaking mini oral presentation of data from its partner CStone Pharmaceuticals’ Phase 3 GEMSTONE-301 study at the European Society for Medical Oncology Congress 2021.
-
In a late-breaking presentation on Saturday, EQRx and partner CStone Pharmaceuticals will report data from the phase III GEMSTONE-301 study of its anti-PD-L1 antibody sugemalimab.
-
Moderna will leverage AbCellera’s AI-powered technology to search and analyze natural immune responses in the hopes of identifying antibodies for up to six targets.
-
EQRx to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
9/7/2021
EQRx to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
-
EQRx Appoints Richard Buckley as Chief Corporate Affairs Officer
8/18/2021
EQRx today announced the appointment of Richard Buckley as chief corporate affairs officer.
-
Money on the Move: August 4 – 10
8/11/2021
Check out where the money went in the life sciences industry this week. -
Messenger RNA has become the life sciences hero of the decade. The lynchpin in the fight against COVID-19, companies are taking mRNA technology to new heights.
-
EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III
8/6/2021
EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and CM Life Sciences III, Inc., a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, announced that they have entered into a definitive business combination agreement.
-
The deal will give EQRx a pre-transaction enterprise value of $3.65 billion and an immediate $1.8 billion in cash that will be used to advance the development of the company’s pipeline.
-
The company struck two separate collaborations over the past two days in order to advance the development of new, innovative medications.
-
EQRx Announces Formation of Mission Advisory Board
7/20/2021
EQRx today announced the formation of its mission advisory board.
-
EQRx Appoints Carlos Garcia-Echeverria, Ph.D., as Chief of Rx Creation
7/1/2021
EQRx, a company committed to developing and delivering important new medicines to patients at radically lower prices, announced the appointment of Carlos Garcia-Echeverria, Ph.D., as chief of Rx creation.
-
EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration to Accelerate the Advancement of New World-Class Medicines
6/24/2021
EQRx, a company committed to developing and delivering important new medicines to patients at radically lower prices, and Exscientia, an AI-driven pharmatech company with a mission to radically improve how drugs are discovered, announced a strategic research and development collaboration agreement.
-
EQRX is pushing forward with its goal of developing more affordable novel medications that can sustain healthcare systems.
-
Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer
5/28/2021
Sugemalimab is the first PD(L)1 monoclonal antibody to demonstrate a progression-free survival benefit in Stage III non-small cell lung cancer (NSCLC) patients after treatment with either concurrent or sequential chemoradiotherapy
-
EQRx Appoints Jami Rubin as Chief Financial Officer and Kent Rogers as Chief Customer Officer
4/19/2021
EQRx , a company committed to developing and delivering important new medicines at lower prices, today announced two key leadership appointments to advance the company’s mission of remaking medicine. Jami Rubin joins as chief financial officer to guide the strategic financial direction of the Company, effective April 5.